Citation

Kim JM, Kim SW, Stewart R, Kim SY, Yoon JS, Jung SW, Lee MS, Yim HW, Jun TY. Hum. Psychopharmacol. 2011; 26(1): 41-50.

Affiliation

Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea. jmkim@chonnam.ac.kr.

Copyright

(Copyright © 2011, John Wiley and Sons)

DOI

10.1002/hup.1168

PMID

21344501

Abstract

OBJECTIVE: To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea. METHODS: For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of ≤7 sustained to 12 weeks or last follow-up, if earlier. RESULTS: For 723 participants, the 12-week remission rate was 31.4%. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety. CONCLUSIONS: Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and a previous suicide attempt were markers of worse outcome. Copyright © 2011 John Wiley & Sons, Ltd.

Language: en